These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A prospective head-to-head comparison of Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429 [TBL] [Abstract][Full Text] [Related]
3. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
4. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963 [TBL] [Abstract][Full Text] [Related]
5. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231 [TBL] [Abstract][Full Text] [Related]
6. Lee H; Eads JR; Pryma DA Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441 [TBL] [Abstract][Full Text] [Related]
7. Head-to-Head Comparison of Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731 [No Abstract] [Full Text] [Related]
8. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Utility of Total Tirosh A; Papadakis GZ; Millo C; Hammoud D; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E Gastroenterology; 2018 Mar; 154(4):998-1008.e1. PubMed ID: 29155309 [TBL] [Abstract][Full Text] [Related]
10. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167 [TBL] [Abstract][Full Text] [Related]
11. The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors. Özkan ZG; Kuyumcu S; Balköse D; Ozkan B; Aksakal N; Yılmaz E; Sanlı Y; Türkmen C; Aral F; Adalet I Mol Imaging Radionucl Ther; 2013 Aug; 22(2):49-55. PubMed ID: 24003397 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Jois B; Asopa R; Basu S Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668 [TBL] [Abstract][Full Text] [Related]
13. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. Pruthi A; Pankaj P; Verma R; Jain A; Belho ES; Mahajan H J Gastrointest Oncol; 2016 Jun; 7(3):449-61. PubMed ID: 27284479 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of hitherto unknown brain meningioma detected on Parghane RV; Talole S; Basu S World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748 [TBL] [Abstract][Full Text] [Related]
15. Tumour-to-liver ratio determined by [ Kim YI; Yoo C; Oh SJ; Lee SJ; Kang J; Hwang HS; Hong SM; Ryoo BY; Ryu JS EJNMMI Res; 2020 Jun; 10(1):63. PubMed ID: 32542576 [TBL] [Abstract][Full Text] [Related]
16. The value of Liu KY; Goldrich DY; Ninan SJ; Filimonov A; Lam H; Govindaraj S; Iloreta AM Head Neck; 2021 Jun; 43(6):E30-E40. PubMed ID: 33786927 [TBL] [Abstract][Full Text] [Related]
18. Cavicchioli M; Bitencourt AGV; Lima ENP Radiol Bras; 2022; 55(1):13-18. PubMed ID: 35210659 [TBL] [Abstract][Full Text] [Related]
19. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Komek H; Ansal Balci T; Can C Asia Ocean J Nucl Med Biol; 2019; 7(2):141-148. PubMed ID: 31380453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]